Where is mRNA vaccine technology headed ... - tlooto, The Most Powerful AcademicGPT

Messenger RNA (mRNA) vaccine technology has matured from an experimental platform to a versatile therapeutic modality. Its success against COVID-19 has catalyzed efforts to apply the same principles—rapid antigen design, scalable manufacturing, and potent immunogenicity—to a spectrum of medical challenges beyond the pandemic. 1. Expanded Infectious-Disease Vaccines Seasonal and emerging viral challenges are prime targets. Influenza vaccines based on mRNA can be updated in weeks to match circulating strains, and clinical candidates have shown robust hemagglutinin-specific responses in phase I trials [1]. Respiratory syncytial virus (RSV) and cytomegalovirus (CMV) mRNA vaccines are in late‐stage development, eliciting both neutralizing antibodies and T cell responses superior to subunit formulations [1]. The agility of the platform suits high-mutation pathogens such as HIV; early immunogenicity studies report cross-clade binding antibodies and CD8+ T cell induction [2][3]. mRNA construct